Buspirone hydrochloride
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Buspirone hydrochloride
- Generic name
- BUSPIRONE HYDROCHLORIDE
- Manufacturer
- AiPing Pharmaceutical, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 55810b17-4796-49d0-90e4-8e075d62eda4
- SPL ID
- 2a9a38df-c46f-437c-ac13-f5256941b1e1
- Version
- 2
- Effective date
- 2026-07-29
- Source export date
- 2026-11-13
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2df682709a18af7b632162dce4573ac151d74d432118e70b8675083d83b89813/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:46:38
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 202087 | derived:openfda.application_number |
| application number | ANDA202087 | openfda.application_number | |
| brand name | Buspirone hydrochloride | openfda.brand_name | |
| generic name | BUSPIRONE HYDROCHLORIDE | openfda.generic_name | |
| manufacturer name | AiPing Pharmaceutical, Inc. | openfda.manufacturer_name | |
| ndc | package | 11788-057-01 | openfda.package_ndc |
| ndc | package | 11788-059-05 | openfda.package_ndc |
| ndc | package | 11788-058-01 | openfda.package_ndc |
| ndc | package | 11788-061-05 | openfda.package_ndc |
| ndc | package | 11788-060-01 | openfda.package_ndc |
| ndc | package | 11788-060-60 | openfda.package_ndc |
| ndc | package | 11788-060-03 | openfda.package_ndc |
| ndc | package | 11788-061-60 | openfda.package_ndc |
| ndc | package | 11788-059-01 | openfda.package_ndc |
| ndc | package | 11788-060-05 | openfda.package_ndc |
| ndc | package | 11788-057-05 | openfda.package_ndc |
| ndc | product | 11788-060 | openfda.product_ndc |
| ndc | product | 11788-057 | openfda.product_ndc |
| ndc | product | 11788-059 | openfda.product_ndc |
| ndc | product | 11788-061 | openfda.product_ndc |
| ndc | product | 11788-058 | openfda.product_ndc |
| ndc11 | package | 11788006105 | derived:openfda.package_ndc |
| ndc11 | package | 11788005801 | derived:openfda.package_ndc |
| ndc11 | package | 11788005905 | derived:openfda.package_ndc |
| ndc11 | package | 11788006001 | derived:openfda.package_ndc |
| ndc11 | package | 11788005701 | derived:openfda.package_ndc |
| ndc11 | package | 11788006160 | derived:openfda.package_ndc |
| ndc11 | package | 11788006005 | derived:openfda.package_ndc |
| ndc11 | package | 11788006003 | derived:openfda.package_ndc |
| ndc11 | package | 11788005901 | derived:openfda.package_ndc |
| ndc11 | package | 11788006060 | derived:openfda.package_ndc |
| ndc11 | package | 11788005705 | derived:openfda.package_ndc |
| rxcui | 866083 | openfda.rxcui | |
| rxcui | 866111 | openfda.rxcui | |
| rxcui | 866090 | openfda.rxcui | |
| rxcui | 866094 | openfda.rxcui | |
| rxcui | 866018 | openfda.rxcui | |
| spl id | 2a9a38df-c46f-437c-ac13-f5256941b1e1 | id | |
| spl set id | 55810b17-4796-49d0-90e4-8e075d62eda4 | set_id | |
| unii | 207LT9J9OC | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS The administration of buspirone hydrochloride tablets to a patient taking a monoamine oxidase inhibitor (MAOI) may pose a hazard. There have been reports of the occurrence of elevated blood pressure when buspirone hydrochloride has been added to a regimen including an MAOI. Therefore, it is recommended that buspirone hydrochloride tablets not be used concomitantly with an MAOI.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS (See also PRECAUTIONS ) Commonly Observed The more commonly observed untoward events associated with the use of buspirone hydrochloride tablets not seen at an equivalent incidence among placebo-treated patients include dizziness, nausea, headache, nervousness, lightheadedness, and excitement.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.